Eliane Schutte was appointed as Chief Executive Officer at Xeltis in 2018. During her time as CEO, the Company has strengthened and expanded its strategy across vascular applications and closed more than €70 million of funding, including strategic license transactions. Under her leadership, Xeltis began its pivotal trials to obtain market approvals. She initially joined Xeltis in 2015 as Chief Development Officer, leading the clinical trial program, product development strategy and regulatory. Eliane has extensive expertise in global product development and regulatory affairs, with over 25 years in the medtech and biotech industries. Prior to Xeltis, she was Vice President for Global Product Development in peri-operative care at The Medicines Company, Chief Development Officer at Dutch-US biotech start-up Profibrix and Vice President for Regulatory Affairs and EU Operations at IsoTis Orthobiologics. Eliane was included in the list of The Top 50 Healthcare Technology CEOs by the Healthcare Technology Report in 2021 and 2022.

Recent Milestones:

- 4 clinical trials ongoing, in 3 different indications
- Last year completed 44.5 Euro Funding round
- Latest indication - Hemodialysis Access

Upcoming Milestones:

- Complete pivotal trial in hemodialysis access graft
- Continue next Cohort with CABG patient enrollment

Investors: DaVita, EQT, VI, Kurma, Ysios, EIC, Invest-NL, GrandPharma